MDSC recruitment to the tumor site is in part a response to glioma expression of chemokines CCL2 and CCL7, which are ligands of the CCR2 receptor expressed by MDSCs (Takacs et al. (2022)). The gene discussed is CCL2; the disease is neoplasm.